Pretreatment with butorphanol reduces myoclonus after etomidate

Xiaohong Zhao, Rui Bao, Jiali Zhu, Zheng Liu, Yan Meng, Xiaohua Fan, and Jinbao Li

Abstract

1. Etomidate is often used in the induction of general anesthesia with a very stable hemodynamic profile. Myoclonus is a common problem during induction of anesthesia with etomidate, which may be a problem in the non-fasting patient. It has been shown that the incidence of myoclonus is decreased with a variety of opioid agents. Butorphanol is a strong analgesic with both narcotic agonist and antagonistic properties. This study aims to determine the efficacy of butorphanol and fentanyl for prevention of etomidate-induced myoclonus.

2. One hundred-fifty ASA patients, undergoing elective surgery were randomly assigned into 3 groups of 50 each. Butorphanol group received butorphanol 2 mg, fentanyl group received fentanyl 100 μg, and placebo group received normal saline. Ninety seconds after pretreatment patients received etomidate 0.3 mg·kg⁻¹. Assessment of myoclonus with IV etomidate was done by using a four-point scale: 0 = no myoclonus, 1 = mild myoclonus, 2 = moderate myoclonus, and 3 = severe myoclonus during a 60-second period after etomidate injection.

3. In the placebo group 41 (82%) patients had myoclonus after etomidate injection as compared to 12 (24%) and 2 (4%) in the fentanyl and butorphanol groups, respectively (p <0.001).

4. Butorphanol is an effective and safe drug to reduce the etomidate-induced myoclonus without significant effects.

Key words: Etomidate, myoclonus, butorphanol, fentanyl

Methods

Approval for the study was obtained from the hospital research ethics committee and written informed consent obtained from each patient participating in the study. We expected the incidence of myoclonus in the placebo group to be 0.7. Power analyses showed, using an α=0.05 and β =0.95, that for a reduction rate of 0.35 a minimum of 49 patients would have to be included. We decided to include 50 patients per group. Statistical analyses were performed with SPSS 12.0 (SPSS, Chicago, IL). The Chi-squared test and the analyses of variance were used to identify statistical significance. A p value of less than 0.05 was considered statistically significant.

One hundred and fifty ASA patients scheduled for surgery under general anesthesia without neurologic diseases were included. Midazolam 7.5mg was given orally 1h before induction of anesthesia. An intravenous line was inserted in the patients' antecubital fossa after arrival in the operating room, and isotonic saline solution was infused at a rate of 15 to 20 ml·kg⁻¹ per hour. Heart rate, noninvasive arterial blood pressure and oxygen saturation were recorded every minute during the study period.

Patients were allocated in a randomized and double blinded fashion to one of three pretreatment groups (n=50 in each group): butorphanol 2mg, fentanyl 100μg or saline as placebo. The drugs were prepared in a black syringe (2ml) outside the operating room, by a person not involved in the...
There were no significant differences among the groups in Results. Only two of 50 (4%) of the patients pretreated with *p <0.001 vs Placebo group. # p <0.001 vs Fentanyl group.

Table 2. The incidence and severity of myoclonus in all groups.

<table>
<thead>
<tr>
<th></th>
<th>Placebo group (n=50)</th>
<th>Fentanyl group (n=50)</th>
<th>Butorphanol group (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 0</td>
<td>9</td>
<td>38*</td>
<td>48**</td>
</tr>
<tr>
<td>Grade 1</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Grade 2</td>
<td>18</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Grade 3</td>
<td>16</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Total Myoclonus</td>
<td>41</td>
<td>12*</td>
<td>2*</td>
</tr>
</tbody>
</table>

* p <0.001 vs Placebo group. # p <0.001 vs Fentanyl group.

induction of anesthesia. Randomization was achieved using a computer-generated list. The anaesthetist performing the induction and the patient were not aware of the pretreatment drug. The patients were pre-oxygenated and the study drug was infused. After a ninety-second interval, etomidate 0.3 mg·kg−1 (Etomidate-Lipuro®, B. Braun Melsungen, Melsungen Germany) was injected intravenously over 30 seconds. After injection of the test drug, the grade of sedation (none, mild, moderate, severe), nausea, and apnea were recorded. Patients were observed visually for myoclonus, and when present, myoclonus severity was graded one minute after the end of the etomidate injection by a trained physician who was blinded to the treatment groups. Myoclonus was defined as involuntary, short contraction of some muscle fibers, of a whole muscle, or of different muscles of one group, leading to short observable movements of the corresponding body parts. The intensity of myoclonic movement was graded as 0 = no myoclonus, 1 = mild myoclonus, 2 = moderate myoclonus, and 3 = severe myoclonus [3]. One minute after etomidate administration and evolution of myoclonus, rocuronium 0.6 mg·kg−1 was given to facilitate tracheal intubation. At that point, fentanyl 100 μg was given in the placebo group to guarantee adequate anesthesia. No other drugs were used between premedication and the end of induction. The trachea was intubated and anesthesia was maintained with isoflurane or sevoflurane in oxygen.

Results

There were no significant differences among the groups in the patients’ demographic data (Table 1).

Table 1. Patients’ Characteristics. Values are mean(SD) or number.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Fentanyl</th>
<th>Butorphanol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age; years</td>
<td>50±10</td>
<td>47±15</td>
<td>48±13</td>
</tr>
<tr>
<td>Sex(m:f)</td>
<td>25/25</td>
<td>24/26</td>
<td>23/27</td>
</tr>
<tr>
<td>ASA physical status</td>
<td>28/22</td>
<td>26/24</td>
<td>24/26</td>
</tr>
<tr>
<td>Weight; kg</td>
<td>55.5±10.2</td>
<td>58.2±12.2</td>
<td>56.7±13.8</td>
</tr>
<tr>
<td>Height; cm</td>
<td>168±8</td>
<td>166±6</td>
<td>169±10</td>
</tr>
</tbody>
</table>

Number of adult patients who experienced myoclonus during the one-min observation period after an etomidate injection in each treatment group. Placebo group received saline pre-treatment (n=50); Fentanyl group received fentanyl 1 μg/kg pretreatment (n=50); and Butorphanol group received Butorphanol 2mg/kg pre-treatment (n=50). P<0.001 in the incidence of myoclonus for fentanyl group and butorphanol group versus placebo group; Butorphanol group versus fentanyl group, significantly different for the severity of myoclonus.

Discussion

We observed that pretreatment with butorphanol 2 mg or fentanyl 100 μg reduced the incidence and severity of myoclonus associated with IV injection of etomidate (p <0.001). Butorphanol pretreatment was most effective in attenuating the incidence and severity of myoclonus associated with IV injection of etomidate (p <0.001).

Sung et al., found that the butorphanol was a good opioid analgesic for balanced anesthesia [12]. The authors suggested that butorphanol was a better choice than morphine for use in balanced anesthesia techniques because of its comparable analgesic efficacy and amnesia along with lesser postoperative respiratory depression and a shorter recovery room stay. We chose the dose of butorphanol 2mg because it has been shown to be effective in the prevention of pain during the injection of propofol [13]. The analgesia effect of butorphanol 2mg was similar to that of fentanyl 100μg [14]. So, in this study we chose the fentanyl dose (100μg) that was previously used to prevent myoclonus during etomidate induction [7].

The neurologic mechanism of myoclonus after etomidate is unclear. Kugler et al., postulated that inhibitory circuits can be depressed earlier and at lower etomidate concentrations than excitatory neuronal circuits. Doenicke et al.,
observed that myoclonus after etomidate is a phenomenon of subcortical disinhibition like the phenomenon of restless legs during normal human sleep and is not generated by an epileptic focus [3].

Various methods have been used for attenuating myoclonus during IV injection of etomidate. Pretreatment with diazepam or flunitrazepam failed to reduce myoclonus, [16] but midazolam reduced the incidence because of faster onset [17]. Doenicke et al., reported that pretreatment with three different dosages (etomidate 0.03, 0.05 or 0.075 mg/kg IV) of etomidate reduced myoclonus in a trial (n=20) without a control group in premedicated patients [3]. Pretreatment with fentanyl 100µg reduced the incidence of myoclonus to 8% [18]. The use of larger fentanyl dosages, however, increased the incidence of apnea during induction [7]. The incidence of myoclonus after pretreatment with alfentanil 5µg·kg-1 was reported to be 25% [8]. Hueter et al., examined pretreatment with sufentanil 0.3 µg·kg-1 on the incidence and severity of myoclonus after etomidate in female patients [7]. Myoclonus was observed in none of the patients in the sufentanil group, but in 80% of patients in the placebo group. Sixty percent of the patients treated with sufentanil showed some degree of sedation from mild to severe, whereas only 15% in the placebo group. Although it was shown that fentanyl, alfentanil, or sufentanil are effective in reducing myoclonus, these agents are more suitable for longer surgical procedures. During short or outpatient procedures, these agents may cause residual apnea, sedation, nausea, vomiting, and delayed discharge from the hospital. Another opioid with very short onset time, remifentanil (1 µg·kg⁻¹), was very effective in reducing myoclonus after etomidate from 70% in the placebo group to 6.7% in the remifentanil group [10]. However, remifentanil can cause severe bradycardia. Klausen showed that buprenorphine has no influence on the incidence of myoclonus [19]. Guler et al., reported that Mg 2.48 mmol administered 90s before the induction of anesthesia with etomidate was effective in reducing the incidence and severity of etomidate-induced myoclonus and that ketamine did not reduce the incidence of myoclonus [20].

Butorphanol tartrate is a mixed agonist–antagonist with intrinsic activity at receptors of the mu opioid type (morphine like). It is also an agonist at kappa opioid receptors. Its interactions with these receptors in the CNS apparently mediate most of its pharmacological effects, including analgesia. Butorphanol has an analgesic action 5-8 times more potent than morphine, with less respiratory depression, less nausea and vomiting, no undesirable psychomimetic effects and the provision of perioperative amnesia. After IV administration the onset of analgesia occurs rapidly (within 1-2 minute) with peak effect occurring in about 4-5 minutes [21]. The site of action of butorphanol in reducing the myoclonus of etomidate injection is not clear. Manocha et al., examined the effect of butorphanol on convulsive behaviour using maximal electroshock (MES) test [22]. Their results implicated a role for multitude of neurotransmitter systems, i.e., opioid (mu, kappa, delta), NMDA channel, BZD–GABAA chloride channel complex, and GABAB receptors in the anti-MES action of butorphanol. The analgesic action and the sedative effect of butorphanol may contribute to reducing of myoclonus after etomidate administration. Further work is suggested for confirming the mechanism of action of butorphanol in preventing etomidate induced myoclonus.

We used midazolam, a short-acting benzodiazepine, in all patients as premedication one hour before induction of anesthesia for ethical reasons. In spite of midazolam premedication, the incidence of myoclonus was high in the placebo group. Butorphanol has excellent sedative effect alone and especially in combination with other agents such as promethazine [23]. The combination of butorphanol and etomidate may lead to profound sedation, but prolong awakening was not observed in all of our patients.

We conclude that pretreatment with butorphanol 2mg before induction with 0.3 mg·kg-1 etomidate reduces the incidence of myoclonus without any side effects such as sedation, apnea, nausea, or bradycardia. Butorphanol can be a good choice for prevention of myoclonus after etomidate administration. However, it is believed that independent studies will prove further demonstration of its efficacy and tolerability.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ZX and RB: planned study, analyzed data and drafted the manuscript. They contributed equally to the manuscript; JZ: collected and analyzed data; YM: collected and analyzed data; XF and JL: planned study, drafted and revised the manuscript. They contributed equally to the manuscript; ZL: collected data; XZ and RB: planned study, analyzed data and drafted the manuscript.

References


---

**Citation:**